Bayer to pay over a billion dollars in Yaz lawsuit settlements and Yasmin lawsuit settlements reports Reuters. On March 4, 2013 Thompson Reuters News & Insights published an article written by Terry Baynes said “Bayer AG set aside over $1.5 billion in 2012 to cover litigation expenses tied to its Yasmin and Yaz oral contraceptives”. Women that may have been injured may be entitled to a Yaz settlement but should seek help from a Yaz Lawyer and may need to file a Yaz lawsuit.
Bayer recently issued their most recent Stockholder Quarterly Report for third quarter 2012. The report details out gains, losses (including Yaz settlements concerns) and future growth for all segments of the corporation. Yaz and Yasmin fall in the Pharmaceuticals sub group of their healthcare division. According to their latest Stockholder report, healthcare comprises 45.8% of their sales with pharmaceuticals accounting for 26.6% of that. Clearly, the pharmaceutical industry is a very good business niche to be in if they can set aside over a billion dollars for Yaz settlements and still project growth and profit.
Yaz Class Action Lawsuit Information
Yaz lawsuits are not limited to the US say reports. The article published by Thompson Reuters states that Bayer is facing 13 class actions lawsuits in Canada and are expecting more Yaz lawsuits and Yasmin lawsuits to be filed in the US.
The US legal system is slightly different than in Canada. In the US there are no Yaz call action lawsuits. The Yaz lawsuits filed in the US have been grouped together as a multidistrict litigation. In a Yaz class action lawsuit the litigants would not retain their individual status as they do in a multidistrict litigation.
Yaz Lawsuit Commercial Marketing Claims Have Had no Effect
As we have reported in the past, Bayer does not appear to have any intention of slowing down their marketing efforts on Yaz. In the most recent Stockholders report (3rd Qtr 2013) shows a slight decline if Yaz and Yasmin sales but the popular drug still remains among their best-selling pharmaceuticals. Bayer blames sales of the generic equivalent of Yaz/Yasmin for the decline in market share seen by the two medications. Even though some Yaz lawsuits claim death may have been caused by Yaz and Yasmin, Bayer is reporting a projected growth in sales in North America and emerging markets including China and Russia.
Women interested in learning more about Yaz lawsuit settlements should speak with an experienced Yaz lawyer.